Soleno Therapeutics, Inc.

NasdaqCM SLNO

Soleno Therapeutics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -3,806.27%

Soleno Therapeutics, Inc. Net Income Margin is -3,806.27% for the Trailing 12 Months (TTM) ending September 30, 2024. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqCM: SLNO

Soleno Therapeutics, Inc.

CEO	Dr. Anish Bhatnagar M.D.
IPO Date	Nov. 13, 2014
Location	United States
Headquarters	203 Redwood Shores Parkway
Employees	33
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Key trends

Past 5 years